Company / EPS (Diluted)
Ultragenyx Pharmaceutical Inc. EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$8.25
FY2025
5-year range
-$10.12 / -$3.07
FY2021-FY2025
Trend
+18.5%
vs FY2024
Sector context
#195 of 204
Health Care
What the data says
Among 204 Health Care companies, Ultragenyx Pharmaceutical Inc. is in the bottom 4% for eps (diluted). EPS (Diluted) returned to growth in FY2025 after 2 years of decline, reaching $-8.25.
Based on SEC 10-K filings.
-8.25 in FY2025.
Declined from $-6.70 to $-8.25 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 204This company -$8.25 Sector average -$0.89
▼
-830.9% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 18.5% year-over-year.
- Ranks #195 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2018.
- Lowest eps (diluted) in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -2.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$8.25 | +18.5% |
| FY2024 | -$10.12 | -51.0% |
| FY2023 | -$6.70 | -118.2% |
| FY2022 | -$3.07 | +56.9% |
| FY2021 | -$7.12 | -1836.6% |
| FY2020 | $0.41 | +105.8% |
| FY2019 | -$7.12 | -1248.4% |
| FY2018 | $0.62 | +115.7% |
| FY2017 | -$3.96 | -76.0% |
| FY2016 | -$2.25 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026